Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07612878 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Study acronym: STRIDE
StatusRecruiting
PhaseNot specified
SponsorSanofi
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 3 → 7 locations
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 4 of 9 entries
  2. Re-verified, no change to tracked fieldsv4
  3. Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Jul 31, 2026 to Aug 6, 2026
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sanofi
284 trials monitored
See 12 trials at risk
COPD
1,119 trials monitored
See 34 trials at risk
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.
Trial Details
NCT Number NCT07612878
Lead Sponsor Sanofi
Conditions
(from sponsor)		 COPD (Chronic Obstructive Pulmonary Disease)
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 350 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov